Role of amyloid β peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology

Drug Development Research

Volumn 56, Issue 2, 2002, Pages 248-263

  Kar, S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Acetylcholine; Amyloids; Degenerative disorders; Neurodegeneration; Neuromodulation

Indexed keywords

ACETYLCHOLINE; ALPHA BUNGAROTOXIN I 125; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; IODINE 125; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; PERTUSSIS TOXIN; PIRENZEPINE; TAU PROTEIN; TRITIUM;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; FOREBRAIN; HUMAN; HUMAN CELL; MOUSE; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN PROCESSING; RAT; RECEPTOR DENSITY; REVIEW; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 0036592957     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10080     Document Type: Review

References (163)

1. Administration of amyloid β-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo
2. Beta-amyloid induced increase in choline flux across PC12 cell membranes
3. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration
4. Inhibition of tau phosphorylating protein kinase cdk5 prevents β-amyloid-induced neuronal death
5. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
6. Comparative alterations of nicotinic and muscarinic receptor binding sites in Alzheimer's and Parkinson's diseases
7. β-amyloid peptides as direct cholinergic neuromodulators: A missing link
8. The cholinergic hypothesis of geriatric memory dysfunction
9. Vitamin E protects nerve cells from amyloid β protein toxicity
10. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease
11. Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneraion
12. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
13. The cholinergic neuronal phenotype in Alzheimer's disease
14. A longitudinal, behavioral study of senile dementia of the Alzheimer type
15. Pathology of Alzheimer's disease
16. Neurofibrillary tangles and tau phosphorylation
17. Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septphippocampal pathway of aged amyloid precursor protein london mutant transgenic mice
18. Methodological variables in the assessment of β amyloid neurotoxicity
19. β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding
20. 4 amyloid precursor protein
21. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner
22. Neuron loss in APP transgenic mice
23. The amyloid-β peptide and its role in Alzheimer's disease
24. The synthesis and storage of acetylcholine in mammalian cholinergic nerve terminals
25. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes
26. β-amyloid formation as a potential therapeutic target for Alzheimer's disease
27. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity
28. Selective loss of central cholinergic neurons in Alzheimer's disease
29. Structural correlates of cognition in dementia: Quantification and assessment of synapse change
30. Alzheimer's disease. Closing in on gamma-secretase
31. The pathogenesis of senile plaques
32. 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin and amyloid precursor proteins
33. 7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease
34. Alpha2 macroglobulin and the risk of Alzheimer's disease
35. Human memory and the cholinergic system: A relationship to aging?
36. 7 subunit homomers
37. Activation of the voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to β-amyloid
38. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils
39. Cleavage of amyloid β-peptide during constitutive processing of its precursor
40. The cholinergic hypothesis of Alzheimer's disease: A review of progress
41. Alzheimer type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
42. Stable β-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice
43. Cholinergic system and related neuropathological predilection patterns in Alzheimer's disease
44. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity
45. Down patients: Extracellular preamyloid deposits precede neuritic degeneration and senile plaques
46. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into rat nucleus basalis
47. Tau protein and the neurofibrillary pathology of Alzheimer's disease
48. Secreted β-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation
49. Secreted β-APP stimulates MAP kinase and phosphorylation of tau in neurons
50. Apoptotic cell death induced by β-amyloid-42 is cell type dependent
51. Amyloid β-peptide is produced by cultured cells during normal metabolism
52. Amyloid, the presenilins and Alzheimer's disease
53. Cholinotoxic effects of β-amyloid 1-42 peptide on cortical projections of the rat nucleus basalis magnocellularis
54. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events
55. Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors
56. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists
57. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease
58. Genotype and phenotype in Alzheimer's disease
59. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3
60. 1-.42 supresses acetylcholine synthesis
61. Correlative memory deficits. Aβ elevation, and amyloid plaques in transgenic mice
62. Amyloid beta peptide impaired carbachol but not glutamate-mediated phosphoinositide pathways in cultured rat cortical neurons
63. Activation of protein kinase C inhibits cellular production of the amyloid β-protein
64. Memory-related neuronal systems in Alzheimer's disease: An anatomic study
65. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles
66. Alzheimer's disease
67. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717 (PDAPP) transgenic mouse
68. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats
69. Altered processing of Alzheimer amyloid precursor protein in response to neuronal degeneration
70. 75NTR cholinergic basal forebrain septohippocampal pathway
71. Cellular mechanisms for amyloid b-protein activation of rat basal forebrain neurons
72. Tau protein in normal and Alzheimer's disease brain
73. Amyloid-β peptide, substance, and bombesin bind to the serpin-enzyme complex receptor
74. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell surface receptor
75. β-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal formation
76. Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices
77. The cholinergic system in Alzheimer's disease
78. The epidemiology of dementia and Alzheimer's disease
79. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons
80. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine
81. Differential expression of amyloid precursor protein mRNAs in case of Alzheimer's disease and in aged nonhuman primates
82. Structure-function analysis of muscarinic acetylcholine receptors
83. Amyloid beta peptide1-40 and the function of rat hippocampal hemicholinium-3 sensitive choline carriers: Effects of a proteolytic degradation in vitro
84. The regulation of amyloid precursor protein processing by nicotinic cholinergic mechanisms
85. NTR and activates NFκB in human neuroblastoma cells
86. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease
87. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines
88. Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited
89. β-amyloid-induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression β-amyloid precursor protein
90. Differential APP gene expression in rat cerebral cortex, meninges and primary astroglial, microglial and neuronal cultures
91. Effect of ginseng saponins on beta-amyloid-suppressed acetylcholine release from rat hippocampal slices
92. Disruption of the cytoskeleton in Alzheimer's disease
93. Regulation of tau phosphorylation in Alzheimer's disease
94. Candidate gene for the chromosome 1 familial Alzheimer's disease locus
95. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation
96. 7- containing nicotinic receptors on hippocampal neurons
97. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide
98. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity
99. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease
100. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction
101. Physiological diversity of nicotine acetylcholine receptors expressed by vertebrate neurons
102. Regulation of amyloid precursor protein cleavage
103. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
104. Genetic and molecular advances in Alzheimer's disease
105. Risk factors and differential diagnosis of Alzheimer's disease
106. Acetylcholine, aging and Alzheimer's disease
107. Muscarinic receptor subtypes - Pharmacological, molecular biological and therapeutical aspects
108. Role of neurotransmission in the regulation of amyloid β-protein precursor processing
109. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic cholinergic receptor
110. β-amyloid protein-induced Alzheimer's disease animal model
111. Nicotinic and muscarinic receptor subtypes in the human brain: Changes with aging and dementia
112. 11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography
113. Amyloid β neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells
114. Characterization of the acetylcholine reducing effect of the amyloid-beta peptide in mouse SN56 cells
115. Amyloid β-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurones of the basal forebrain
116. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
117. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice
118. Cultured GABA-immunoreactive neurons are resistant to toxicity induced by β-amyloid
119. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state
120. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum
121. Apolipoprotein E polymorphism and Alzheimer's disease
122. Mutant genes in familial Alzheimer's disease and transgenic models
123. Calcium ionophore increases amyloid β-peptide production by cultured cells
124. Cholinergic markers in Alzheimer's disease and the autoregulation of acetylcholine release
125. PD98059 prevents neurite degeneration induced by fibrillar β-amyloid in mature hippocampal neurons
126. Pharmacological characterization of nicotine-induced acetylcholine release in the rat hippocampus in vivo: Evidence for a permissive dopamine synapse
127. Cholinergic and amyloid precursor protein metabolism
128. Activation of m1 muscarinic acetylcholine receptor regulates τ phosphorylation in transfected PC12 cells
129. Beta-amyloid peptides inhibit acetylcholine release from cholinergic nerve endings isolated from an electric ray
130. Nicotinic acetylcholine receptors in Alzheimer's disease
131. Alzheimer's disease: Genes, proteins and therapy
132. In search of gamma-secretase: Presenilin at the cutting edge
133. Isolation and quantification of soluble Alzheimer β-peptide from biological fluids
134. β-amyloid and ionophore A23187 evoke tau hyper-phosphorylation by distinct intracellular pathways: Differential involvement of the calpain/protein kinase C system
135. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
136. Production of Alzheimer's β protein by normal proteolytic processing
137. Evidence that β-amyloid protein in Alzheimer's disease is not derived by normal processing
138. Molecular genetics of Alzheimer disease
139. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
140. Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology
141. Activation of tau protein kinase I/glycogen synthase kinase-3 beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons
142. Neuropathology in the Down's syndrome brain
143. Senile dementia of the Alzheimer type
144. Regulation of acetylcholine synthesis in the brain
145. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
146. Amyloid β peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats
147. Alteration in working memory but not cholinergic receptor binding sites in transgenic mice expressing human presenilin 1 transgenes
148. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation
149. i protein
150. 7 nicotinic acetylcholine receptors
151. 7 nicotinic acetylcholine receptor with high affinity: Implications for Alzheimer's disease pathology
152. Coupling of muscarinic receptors to GTP proteins in postmortem human brain-alterations in Alzheimer's disease
153. The synthesis and release of acetylcholine by depolarized hippocampal slices is increased by increased choline available in vitro prior to stimulation
154. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
155. Biology of Aβ amyloid in Alzheimer's disease
156. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid β-protein production in human NT2N cells
157. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes
158. Presynaptic nicotinic ACh receptors
159. Choline metabolism as a basis for the selective vulnerability of cholinergic neurones
160. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
161. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease
162. Mechanisms of neuronal degeneration in Alzheimer's disease
163. Amyloid β peptide induces tau phosphorylation and neuronal degeneration in rat primary septal cultured neurons